title: Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease.
abstract: We studied the effect of olanzapine (1 to 15 mg/d) in 15 nondemented parkinsonian patients with drug-induced psychosis. Psychotic symptoms decreased significantly during treatment, and there was no worsening of extrapyramidal symptoms. These results suggest that olanzapine is a well-tolerated and effective treatment for drug-induced psychosis in nondemented patients with Parkinson's disease.
authors.affiliation: Graduate School of Neurosciences Amstordam, The Netherlands.
authors.forename: E C
authors.initials: EC
authors.lastname: Wolters
authors.forename: E N
authors.initials: EN
authors.lastname: Jansen
authors.forename: H G
authors.initials: HG
authors.lastname: Tuynman-Qua
authors.forename: P L
authors.initials: PL
authors.lastname: Bergmans
mesh_terms: D000368:Aged; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D010300:Parkinson Disease / Q000188:drug therapy*; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D000077152:Olanzapine